|
| 32318621 | A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. | Alzheimers Dement (N Y) | 2020 |
| 31162800 | The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics. | Clinical and Translational Science | 2019 |
| 29110507 | Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice. | Experimental Biology and Medicine | 2018 |
| 29354287 | A robust targeted sequencing approach for low input and variable quality DNA from clinical samples. | NPJ Genom Med | 2018 |
| 25757705 | Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. | Orphanet Journal of Rare Diseases | 2015 |
| 23961847 | The current status of biomarkers for predicting toxicity. | Expert Opin Drug Metab Toxicol | 2013 |
| 22471322 | Challenges of biomarkers in drug discovery and development. | Expert Opinion on Drug Discovery | 2012 |
| 22970228 | Technical reproducibility of genotyping SNP arrays used in genome-wide association studies. | PLoS One | 2012 |
| 22037040 | Quantifying factors for the success of stratified medicine. | Nature Reviews Drug Discovery | 2011 |
| 23484625 | Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. | Expert Opinion on Medical Diagnostics | 2011 |
| 21448748 | Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. | AAPS J | 2011 |
| 20406066 | Molecular biomarkers: a US FDA effort. | Biomark Med | 2010 |
| 20676074 | The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. | Nat Biotechnol | 2010 |
| 20676072 | Assessment of variability in GWAS with CRLMM genotyping algorithm on WTCCC coronary artery disease. | Pharmacogenomics J | 2010 |
| 20676071 | Batch effects in the BRLMM genotype calling algorithm influence GWAS results for the Affymetrix 500K array. | Pharmacogenomics J | 2010 |
| 20676070 | Variability in GWAS analysis: the impact of genotype calling algorithm inconsistencies. | Pharmacogenomics J | 2010 |
| 20811041 | Translational medicine and the value of biomarker qualification. | Science Translational Medicine | 2010 |
| 20514070 | Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. | Nat Rev Drug Discov | 2010 |
| 20458315 | Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. | Nature Biotechnology | 2010 |
| 20458314 | Towards consensus practices to qualify safety biomarkers for use in early drug development. | Nature Biotechnology | 2010 |
| 20458312 | Evolution of biomarker qualification at the health authorities. | Nature Biotechnology | 2010 |
| 20368714 | Assessing sources of inconsistencies in genotypes and their effects on genome-wide association studies with HapMap samples. | Pharmacogenomics J | 2010 |
| 20407457 | The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. | Clinical Pharmacology and Therapeutics | 2010 |
| 19958096 | Development of an undergraduate pharmacogenomics curriculum. | Pharmacogenomics | 2009 |
| 19710639 | Novel biomarkers of acute kidney toxicity. | Clinical Pharmacology and Therapeutics | 2009 |
| 19102722 | Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. | Pharmacogenomics | 2009 |
| 18776163 | Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV inhibitor SCH 351591 or SCH 534385. | Toxicologic Pathology | 2008 |
| 19025421 | Modulation of clopidogrel pharmacodynamic response. | Pharmacotherapy | 2008 |
| 18093264 | Qualification of biomarkers for drug development in organ transplantation. | Am J Transplant | 2008 |
| 18280028 | Strategic paths for biomarker qualification. | Toxicology | 2008 |
| 18793455 | The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. | BMC Bioinformatics | 2008 |
| 18776166 | Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385. | Toxicologic Pathology | 2008 |
| 18447634 | The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". | OMICS | 2008 |
| 18802418 | The next steps for genomic medicine: challenges and opportunities for the developing world. | Nat Rev Genet | 2008 |
| 17259954 | The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. | Clinical Pharmacology and Therapeutics | 2007 |
| 24980840 | The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path. | Drug Discovery Today: Technologies | 2007 |
| 24980714 | Questions and answers about the Pilot Process for Biomarker Qualification at the FDA. | Drug Discovery Today: Technologies | 2007 |
| 24980713 | An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path Initiative. | Drug Discov Today Technol | 2007 |
| 21136652 | Grand rounds in proteomics at the FDA white oak, silver spring, MD, USA, april 3, 2007. | Proteomics - Clinical Applications | 2007 |
| 17567848 | Implementing the U.S. FDA guidance on pharmacogenomic data submissions. | Environmental and Molecular Mutagenesis | 2007 |
| 17408233 | Biomarker qualification pilot process at the US Food and Drug Administration. | AAPS Journal | 2007 |
| 16886901 | Process map proposal for the validation of genomic biomarkers. | Pharmacogenomics | 2006 |
| 20021001 | Application of pharmacogenomics in clinical pharmacology. | Toxicol Mech Methods | 2006 |
| 20020998 | Gaining Confidence on Molecular Classification through Consensus Modeling and Validation. | Toxicol Mech Methods | 2006 |
| 16964229 | The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. | Nat Biotechnol | 2006 |
| 16964225 | Evaluation of DNA microarray results with quantitative gene expression platforms. | Nat Biotechnol | 2006 |
| 17061323 | Rat toxicogenomic study reveals analytical consistency across microarray platforms. | Nat Biotechnol | 2006 |
| 16179916 | The External RNA Controls Consortium: a progress report. | Nat Methods | 2005 |
| 16041391 | The need for education in pharmacogenomics: a regulatory perspective. | Pharmacogenomics J | 2005 |
| 16026597 | Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. | BMC Bioinformatics | 2005 |